Answers are grounded in this paper and cite their sources.
Assesses new integrated strategies for HCC treatment, suggesting innovative biomarker systems.
肝细胞癌(Hepatocellular Carcinoma,HCC)具有极高的时空异质性与复杂的免疫微环境,导致其在临床治疗中面临免疫治疗响应率低,且容易发生耐药。本文综合考虑肝脏独特的生理性免疫耐受机制,深入探讨了HCC如何通过重塑“胎肝样(Onco-fetal)”癌胚生态系统来实现免疫逃逸的底层逻辑。在此基础上,本文系统梳理了以免疫检查点抑制剂为基础的单药或者联合疗法在临床应用中的最新进展和局限性,前瞻性地提出了以磷脂酰肌醇蛋白聚糖-3(Glypican-3,GPC3)等癌胚抗原为核心的“诊疗一体化”靶向干预策略。为了打破“同病异效”的临床困局,改变经验性的系统给药模式,本文提出亟需构建涵盖静态分子图谱、空间免疫景观与动态演变监测(如ctDNA-MRD、影像组学)的多维生物标志物体系,旨在为HCC的精准分层与个体化治疗提供坚实的理论支撑。
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: